Key US Entresto Barriers Are PA Process & Co-Payments

Key US Entresto Barriers Are PA Process & Co-Payments – BMT Poll

17 May 2016

• By Sten Stovall

Uptake of Novartis AG's heart failure drug Entresto in the US has been slow following approval in July 2015, partly due to the time it has taken to secure insurance coverage, but physicians also complain about other insurance barriers, a new survey by BioMedTracker shows.

Pills in hand — Entresto Uptake In The US Has Been Slow • Source: Shutterstock

A BioMedTracker poll canvassing 23 US-based cardiologists about the main clinical and reimbursement hurdles causing the slow uptake there of Novartis's heart failure drug Entresto (valsartan/sacubitril) suggests insurance issues - namely pre-authorization and high co-payments - are the key causes. More than a third of respondents also listed reluctance to switch patients doing well on current medications, while only 9-13% listed lack of confidence about efficacy, concerns about hypotension, or titration issues as important barriers.

These were the main takeaways from replies by cardiologists to questions about the major barriers preventing use of Entresto in Class II-IV heart failure patients with reduced ejection fraction (HFrEF),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

26 May 2025

• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

20 May 2025

• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

30 May 2025

• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.